#South Korea #Chicago #Seegene #CURECA #STAgora

Seegene Unveils the Future of PCR Testing at ADLM 2025

The global leader in molecular diagnostics, Seegene Inc., has made headlines at the ADLM 2025 conference in Chicago by introducing its groundbreaking unattended PCR automation system known as CURECA™. This fully automated testing platform not only streamlines laboratory processes but also promises to redefine diagnostic procedures globally.

The Dawn of Unattended PCR Testing

Seegene’s CURECA™ system sets a new benchmark in the diagnostic industry by automating every step of the PCR testing process. This includes sample storage, preprocessing, nucleic acid extraction, amplification, and analysis, all conducted without any human intervention. The design is conducive for continuous operation 24/7, which significantly minimizes human errors and improves the consistency and reliability of test results.

At the core of CURECA™ is a fully automated preparation module, tackling one of the most error-prone phases in laboratory workflows: sample preprocessing. Traditionally, this step has been a major challenge due to the varied nature of samples, including urine, blood, sputum, and stool. Manual tasks executed by lab technicians often lead to inconsistencies in results due to differences in skill levels among personnel. Stool samples, in particular, have posed significant obstacles for automation due to their viscosity and solid components requiring meticulous manual handling.

CURECA™ is the first system capable of automating the preprocessing of all major sample types, including stool, effectively overcoming longstanding barriers in laboratory operations. This innovation reduces labor demands, increases sample throughput, and enhances overall operational and cost efficiencies. Consequently, laboratory personnel can shift their focus from manual processing to higher-level responsibilities such as data analysis and clinical interpretation. This transition allows labs to optimize their workforce in high-volume testing environments, providing sustainable high-quality test results around the clock.

Additionally, CURECA’s preparatory module is adaptable beyond PCR diagnostics. It facilitates preprocessing for other fields such as clinical chemistry and immunoassays, representing a significant advancement in the broader diagnostics market. Its modular architecture allows for customizable configurations to meet the specific needs of every laboratory’s size and layout.

STAgora™: Empowering Clinical Decision-Making with Real-Time Data

Alongside CURECA™, Seegene also introduced STAgora™ at ADLM 2025. This sophisticated platform is designed to gather and analyze PCR diagnostic data in real-time, aiding clinical decision-making. By compiling test data uploaded from hospitals worldwide, it offers an integrated view of regional infection trends, positivity rates, and co-infection patterns.

STAgora™ provides more than 40 tailored statistical tools aimed at facilitating clinical support. With this platform, healthcare providers can compare individual patient test results with local and regional epidemiological data, leading to more accurate data-driven treatment strategies. Moreover, it enables physicians to assess infection trends at both patient and community levels, enhancing diagnostic accuracy and care planning timelines. The fast and reliable insights generated by such comprehensive analysis are expected to position STAgora™ as an essential tool for clinical decision-making.

Expanding Global Collaboration

Following its participation in ADLM 2025, Seegene aims to broaden access to the benefits of CURECA™ and STAgora™ by sharing its knowledge gained from initial pilot projects and forging new global partnerships. Earlier this year, CURECA™ drew significant interest at the ESCMID Global 2025 conference, a leading European event in clinical microbiology and infectious diseases.

To bolster its research, development, and manufacturing capabilities within the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer of Seegene, emphasized that CURECA™ and STAgora™ represent more than just diagnostic tools or software. They signify a new global standard aimed at redefining aspects of diagnostics in clinical settings across the globe.

“We remain committed to sharing the many technological assets we have built over the years, thereby driving fundamental innovations throughout the global diagnostic ecosystem,” said Shin.

Conclusion

In conclusion, as Seegene continues to lead the charge in molecular diagnostics with innovations like CURECA™ and STAgora™, the future of diagnostic testing looks promising. By addressing long-standing challenges and enhancing operational efficiencies, Seegene is setting a new standard for laboratories worldwide, ensuring that quality diagnostics are accessible and efficient for all healthcare providers.

For more information about Seegene and their innovations, visit Seegene.com or follow them on LinkedIn.